<DOC>
	<DOCNO>NCT00154050</DOCNO>
	<brief_summary>The study design test hypothesis high dose candesartan treatment compare quinapril able reduce intima hyperproliferation restenosis rate stent angioplasty peripheral occlusive artery disease .</brief_summary>
	<brief_title>High Dose Candesartan Versus Quinapril Restenosis Prophylaxis After Stent Angioplasty</brief_title>
	<detailed_description>Patients randomly assign treatment either candesartan 32 mg/d Quinapril 20 mg/d angioplasty . Walking distance , intima medium thickness crurobrachial pressure ratio compare 6 week , 3 month 6 month . After 6 month angiographic control perform .</detailed_description>
	<mesh_term>Arterial Occlusive Diseases</mesh_term>
	<mesh_term>Candesartan</mesh_term>
	<mesh_term>Candesartan cilexetil</mesh_term>
	<mesh_term>Quinapril</mesh_term>
	<criteria>male female peripheral occlusive arterial disease Stad IIb Fontaine classification patient lesion available PTA renal insufficiency patient calciumantagonists</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2006</verification_date>
	<keyword>restenosis</keyword>
	<keyword>intima hyperproliferation</keyword>
	<keyword>stent angioplasty</keyword>
	<keyword>pain-free walking distance</keyword>
</DOC>